Biotechnology Shares of USA-based Iveric bio, previously known as Ophthotech Corp, leapt almost 80% to $1.67 in early trading today, after it announced initial top-line data confirming that Zimura (avacincaptad pegol), the company’s complement factor C5 inhibitor, met its prespecified primary endpoint in reducing the rate of geographic atrophy (GA) growth in patients with dry age-related macular degeneration (AMD) in a randomized, controlled Phase IIb clinical trial. 28 October 2019